HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Journal
International journal of breast cancer
ISSN: 2090-3170
Titre abrégé: Int J Breast Cancer
Pays: Egypt
ID NLM: 101568103
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
09
05
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship between patterns of HER2 testing results and response to NAC. We evaluated clinicopathologic characteristics associated with RCB categories in HER2+ patients who underwent HER2-directed NAC. A retrospective chart review was conducted with Stage I-III HER2+ breast cancer cases following NAC and surgical resection. HER2 immunohistochemistry (IHC) staining and fluorescence in situ hybridization (FISH), histologic/clinical characteristics, hormone receptor status, and RCB scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated. 64/151 (42.4%) patients with HER2+ disease had pathologic complete response (pCR). Tumors with suboptimal response (RCB-II and RCB-III) were more likely to demonstrate less than 100% HER2 IHC 3+ staining ( HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.
Identifiants
pubmed: 34123431
doi: 10.1155/2021/6684629
pmc: PMC8166502
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6684629Informations de copyright
Copyright © 2021 Tamera J. Lillemoe et al.
Déclaration de conflit d'intérêts
The authors report no conflict of interest pertaining to this work.
Références
Breast Cancer Res Treat. 2014 May;145(1):143-53
pubmed: 24682674
Arch Pathol Lab Med. 2016 Apr 15;140(11):1250-1258
pubmed: 27081877
JAMA Oncol. 2016 Aug 1;2(8):1040-7
pubmed: 27100299
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Clin Breast Cancer. 2013 Apr;13(2):146-52
pubmed: 23318089
Mod Pathol. 2012 Jul;25(7):938-48
pubmed: 22388760
Int J Cancer. 2018 Feb 15;142(4):844-853
pubmed: 29023765
J Clin Oncol. 2016 Oct 10;34(29):3518-3528
pubmed: 27573653
Clin Breast Cancer. 2020 Feb;20(1):19-24
pubmed: 31806448
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Arch Pathol Lab Med. 2010 Jun;134(6):930-5
pubmed: 20524870
Breast J. 2010 Jul-Aug;16(4):362-8
pubmed: 20443786
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Mod Pathol. 2015 Jul;28(7):913-20
pubmed: 25932963
J Breast Cancer. 2013 Dec;16(4):395-403
pubmed: 24454461
Ann Oncol. 2017 Oct 1;28(10):2420-2428
pubmed: 28961844
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Mod Pathol. 2014 Jan;27(1):4-18
pubmed: 23807776
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Am J Clin Pathol. 2009 May;131(5):678-82
pubmed: 19369627
Breast Cancer Res Treat. 2017 Nov;166(2):447-457
pubmed: 28799059
Lab Invest. 2014 Jan;94(1):98-106
pubmed: 24189270
Breast. 2014 Aug;23(4):466-72
pubmed: 24742606
Hum Pathol. 2014 Feb;45(2):249-58
pubmed: 24289969
J Clin Oncol. 2016 Feb 20;34(6):542-9
pubmed: 26527775
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Breast Cancer Res Treat. 2015 Apr;150(3):581-8
pubmed: 25762478
Breast Cancer Res Treat. 2019 Aug;177(1):61-66
pubmed: 31144151
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Ann Oncol. 2013 Aug;24(8):1999-2004
pubmed: 23562929
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
Breast Cancer Res. 2018 Apr 16;20(1):27
pubmed: 29661243